Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

While PrEP pills have been an important tool in HIV prevention, we now have something potentially far more transformative: lenacapavir, recently named Science Magazine’s 2024 “Drug of the Year.” ...

Lenacapavir, a bi-annual injectable treatment for HIV prevention (PrEP), is being celebrated as a major advancement in the field following new study results showing a 96% reduction in HIV cases.

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

More from the Fact-Check Team: How we pick and research claims | Email newsletter | Facebook page The post appears to reference the drug lenacapavir, which reportedly can cost around $40,000 ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV with only two injections per year. But it needs to be cheaper to be ...

Lenacapavir 463.5mg/1.5mL (309mg/mL); soln for SC inj; preservative-free. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between ...

Lenacapavir was filed for U.S. approval for twice-yearly HIV prevention. A mid-2025 launch is anticipated, with access expected to reach 75% within six months. European submissions are under ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...

“From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PrEP in Summer 2025, with its unique opportunity to extend the reach of HIV ...

Lenacapavir requires just two injections a year and has shown remarkable success in trials. But it currently costs each patient more than $40,000 a year.

The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma.